Literature DB >> 15984630

Cumulative irritation potential of adapalene 0.1% cream and gel compared with tazarotene cream 0.05% and 0.1%.

Jonathan S Dosik1, Kenneth Homer, Stéphanie Arsonnaud.   

Abstract

Despite the many beneficial effects of dermatologic applications, most of the current treatments for acne cause local irritation. The objective of this study was to compare the ability of the epidermis to tolerate adapalene 0.1% cream and gel and tazarotene cream in concentrations of 0.05% and 0.1%. A total of 30 subjects were enrolled in the study. The test products were applied under occlusive dressings at randomized sites on the upper back for approximately 24 hours, 4 times a week, and for 72 hours, once a week, for a period of 3 weeks. Skin reactions (erythema score plus other local reactions) at the product application sites were assessed 15 to 30 minutes after dressing removal. Twenty-six subjects completed the study. A total of 16 subjects discontinued use of 1 or more of the test products because of irritation scores reaching severe or greater; all but one of these discontinuations were at sites treated with the tazarotene products. The mean 21-day cumulative irritancy indices for adapalene 0.1% cream and gel were significantly lower (P=.05) than those for tazarotene cream 0.05% and 0.1% and not notably higher than that of the negative control product.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15984630

Source DB:  PubMed          Journal:  Cutis        ISSN: 0011-4162


  2 in total

1.  A review of the use of adapalene for the treatment of acne vulgaris.

Authors:  Suleyman Piskin; Erol Uzunali
Journal:  Ther Clin Risk Manag       Date:  2007-08       Impact factor: 2.423

2.  A dermocosmetic containing bakuchiol, Ginkgo biloba extract and mannitol improves the efficacy of adapalene in patients with acne vulgaris: result from a controlled randomized trial.

Authors:  Katarína Poláková; Aurélie Fauger; Michèle Sayag; Eric Jourdan
Journal:  Clin Cosmet Investig Dermatol       Date:  2015-04-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.